- Business Wire
Avioq, Inc. has received CE Marking (Conformité Européenne) and has begun marketing their VioOneâ„¢ HIV Profileâ„¢ Supplemental Assay in the European Union and other CE Mark countries.
The product has also been submitted for FDA approval. "We are pleased to provide the CE Mark HIV Profileâ„¢ assay to countries outside the U.S.," said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, "We are also looking for distribution partners to expand the global availability."
The HIV Profileâ„¢ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation.
About Confirmatory Testing
In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a supplemental assay that can detect and differentiate HIV-1 and HIV-2 for confirmation of repeatedly reactive HIV-1/HIV-2 screening results. Historically in the USA, this has been done using an FDA approved Western Blot or IFA assay. The HIV Profileâ„¢ assay is an improved, faster and easier alternative with performance that aligns with the algorithm.
About Avioq
Avioq, Inc., located in Research Triangle Park, North Carolina, is a medical device company established to develop and market high-quality immunodiagnostic products. Avioq is committed to working closely with its customers to meet their needs and provide the highest quality service. For more information about the VioOneâ„¢ HIV Profileâ„¢ Supplemental Assay, visit www.avioq.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005461/en/
